DENVER, CO / ACCESS Newswire / May 18, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central ...

Aspera’s 11th ISS mission overall — now operating in microgravity to advance development of an oral Rebecsinib formulation ...

Series of high-quality acquisitions expands Clarion’s footprint in senior housing,  outpatient medical, and inpatient ...

Research Describes the Potential of JCR’s Platform Technologies, Including JUST-AAV Gene Therapy, to Facilitate Delivery of Therapies to the Central Nervous System -HYOGO, Japan--(BUSINESS WIRE)--JCR ...

Binding term-sheet for a potential aggregate amount of up to USD 200 million and tiered royaltiesVILLEJUIF, France--(BUSINESS WIRE)--Regulatory News:Valerio Therapeutics (FR0010095596 – ALVIO), a ...

Their recognized expertise will help accelerate the strategic transformation launched in 2025Subject to approval at upcoming Annual General MeetingPARIS & BOSTON--(BUSINESS WIRE)--Regulatory ...

Category-specific honors identify client-rated leaders in data-ready EHRs, interoperability, enterprise imaging, cloud, cybersecurity, AI, advisory, analytics, clinical decision support and digital ...

Five issued U.S. patents cover the combination of ImmunityBio’s IL-15 receptor agonist (NAI) with Bacillus Calmette-Guérin ...

SMPA reinforces commitment to the urology community with findings from studies across overactive bladder and advanced ...

Positive PROSERA CT FRI Results Demonstrated Multiple Statistically Significant Treatment Effects, Including Novel Signals Correlated with Clinical Outcomes -- Gossamer Announces Commencement of ...

Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH ...

Million in Q1 Net Income Driven by $2.2 Million Unrealized Gain on TAO HoldingsEight Months of Bittensor Subnet Diligence Has Sharpened the Company’s View of Where Its Operating Experience Can Be Most ...